KERRI A KISSELL

Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism GREENFIELD, IN NPI 1043354483

General Payments — all program years on this page

$81,001.93

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 276
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $378.53 across 20 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $378.5320

By paying entity

Latest program year (PY2024) · sorted by reported total.

By program year

Program yearAmountRecords
2018 $22,800.7054
2019 $38,485.8056
2020 $6,630.6922
2021 $6,714.4425
2022 $966.0135
2023 $5,025.7664
2024 $378.5320

Records — PY2024 (20)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1096567680 Novo Nordisk Inc $23.08 02/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1097639068 Novo Nordisk Inc $17.36 04/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1097719152 Novo Nordisk Inc $13.84 02/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116804368 Insulet Corporation $27.63 05/03/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116804370 Insulet Corporation $15.14 02/23/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117039198 Medtronic, Inc. $15.22 04/19/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117736266 Corcept Therapeutics $22.99 02/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117849271 Boehringer Ingelheim Pharmaceuticals, Inc. $16.33 01/26/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117849273 Boehringer Ingelheim Pharmaceuticals, Inc. $19.08 02/23/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1126844056 CeQur Corporation $26.44 01/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135077653 Lilly USA, LLC $14.40 01/11/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135101464 Lilly USA, LLC $17.69 02/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135101466 Lilly USA, LLC $18.93 02/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135106507 Lilly USA, LLC $15.00 01/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135118919 Lilly USA, LLC $16.32 04/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1144601557 Xeris Pharmaceuticals, Inc. $18.01 02/23/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1144601559 Xeris Pharmaceuticals, Inc. $24.69 04/02/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1144601561 Xeris Pharmaceuticals, Inc. $21.06 02/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1151811244 Chiesi USA, Inc. $19.84 03/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1153288870 Ultragenyx Pharmaceutical Inc. $15.48 05/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.